Research summary
CagriSema
An investigational fixed combination of the long-acting amylin analog cagrilintide and the GLP-1 agonist semaglutide.
Metabolic CombinationFixed combination (cagrilintide + semaglutide)AAsTwo co-formulated peptidesMWNot applicable (combination)CASNot applicable (combination)Safety7/10NCAANot listed
Evidence at a glance
What the research says about CagriSema
The CagriSema evidence base cited here is 4 sources — 3 clinical, 1 preclinical. Its strongest evidence is human — 3 clinical studies, most recently 2026 ("CagriSema REIMAGINE 2 Phase 3 Trial Results"). Regulatory status: Phase III (not yet approved).
Key findings
What the literature shows
- Fixed-ratio combination of cagrilintide (amylin analogue) + semaglutide (GLP-1 agonist) in a once-weekly subcutaneous injection — dual complementary mechanisms targeting satiety, gastric emptying, and energy expenditure.
- REIMAGINE Phase 2/3 trials demonstrated ~25% mean body weight loss at 68 weeks, with significant improvements in HbA1c, waist circumference, and blood pressure.
- Superior to either component alone, supporting the hypothesis that combinatorial incretin/amylin signaling is more effective than any single-pathway approach.
Citations
4 peer-reviewed sources
All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.
Clinical3 sources
Related research